{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:46:58Z","timestamp":1792874818416,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.cpcardiol.2024.102779","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T01:55:49Z","timestamp":1722390949000},"page":"102779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["In-hospital initiation of sodium-glucose cotransporter-2 inhibitors in patients with heart failure and reduced ejection fraction: 90-day prescription patterns and clinical implications"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3999-1265","authenticated-orcid":false,"given":"Lucrecia Mar\u00eda","family":"Burgos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco Nicol\u00e1s","family":"Ballari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Spaccavento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Leonardo","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo Consuelo","family":"Baro Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Antonella","family":"De Bortoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirta","family":"Diez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2024.102779_bib0001","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.483","article-title":"Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review","volume":"18","author":"van Riet","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global Public Health Burden of Heart Failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0003","first-page":"1787","article-title":"ESC Guidelines for the diagnosis and treatment of acute chronic heart failure 2012","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0004","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2012.09.038","article-title":"Rehospitalization for heart failure: problems and perspectives","volume":"61","author":"Gheorghiade","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102779_bib0005","first-page":"S1","article-title":"Strategies to reduce hospitalization in the management of heart failure","volume":"10","author":"Berkowitz","year":"2005","journal-title":"Lippincotts Case Manag"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0006","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.cpcardiol.2024.102779_bib0007","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"Writing Committee","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0008","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.cpcardiol.2024.102779_bib0009","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empaglifozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cpcardiol.2024.102779_bib0010","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapaglifozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2024.102779_bib0011","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotaglifozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.cpcardiol.2024.102779_bib0012","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empaglifozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"n engl j med"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ahj.2020.10.064","article-title":"Efect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes\u2014systematic review and meta-analysis of randomized placebo-controlled trials","volume":"232","author":"Salah","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0014","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2020.12.007","article-title":"Efects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: a meta-analysis update","volume":"233","author":"Salah","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0015","article-title":"Efect of empaglifozin in patients with heart failure across the spectrum of left ventricular ejection fraction","author":"Butler","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0016","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ejhf.1459","article-title":"QUALIFY Investigators. Physicians\u2019 guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry","volume":"21","author":"Komajda","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0017","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/ehf2.13223","article-title":"Adherence and optimization of angiotensin converting enzyme inhibitor\/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure","volume":"8","author":"Carubelli","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0018","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/ejhf.2271","article-title":"Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)","volume":"23","author":"Savarese","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0019","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2021.18","article-title":"The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction","volume":"7","author":"Brownell","year":"2021","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0021","first-page":"ehac103","article-title":"Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction","author":"Tromp","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0022","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0023","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0024","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/ejhf.1793","article-title":"Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0025","first-page":"1","article-title":"Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization","volume":"7","author":"Bhagat","year":"2019","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0026","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrcardio.2015.14","article-title":"The vulnerable phase after hospitalization for heart failure","volume":"12","author":"Greene","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0027","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.pcad.2020.04.007","article-title":"Acute heart failure: more questions than answers","volume":"63","author":"Tomasoni","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"issue":"7","key":"10.1016\/j.cpcardiol.2024.102779_bib0028","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure: optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0029","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ahj.2013.03.007","article-title":"Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure","volume":"165","author":"Curtis","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0030","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.cardfail.2021.03.012","article-title":"Sacubitril\/valsartan initiation and post-discharge adherence among patinets hospitalized for heart failure","volume":"27","author":"Carnicelli","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0031","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamacardio.2020.7585","article-title":"Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction","volume":"6","author":"Berg","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2024.102779_bib0032","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced Trial","volume":"143","author":"Packer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0033","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"SOLOIST-WHF Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0034","unstructured":"Emparesponse."},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0035","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","article-title":"Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF)","volume":"41","author":"Serenelli","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.cpcardiol.2024.102779_bib0036","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12933-022-01455-2","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis","volume":"21","author":"Salah","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0037","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","article-title":"Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists: an analysis of DAPA-HF","volume":"9","author":"Shen","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"11","key":"10.1016\/j.cpcardiol.2024.102779_bib0038","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jacc.2021.02.006","article-title":"Quadruple Medical Therapy for Heart Failure: Medications Working Together to Provide the Best Care","volume":"77","author":"Greene","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0039","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ahj.2021.09.009","article-title":"Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018","volume":"243","author":"Salah","year":"2022","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102779_bib0040","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/ejhf.2397","article-title":"Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"20","key":"10.1016\/j.cpcardiol.2024.102779_bib0041","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.jacc.2021.08.064","article-title":"In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction","author":"Rao","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"10367","key":"10.1016\/j.cpcardiol.2024.102779_bib0042","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2024.102779_bib0043","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.amjcard.2022.09.019","article-title":"Impact of Inpatient Initiation of Sodium-Glucose Cotransporter-2 Inhibitors on Prescription Rates in Patients With Heart Failure With Reduced Ejection Fraction","volume":"186","author":"Okoroike","year":"2023","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2024.102779_bib0044","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"-Voors","year":"2022","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.cpcardiol.2024.102779_bib0045","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.jacc.2023.02.029","article-title":"Virtual Care Team Guided Management of Patients With Heart Failure During Hospitalization","volume":"81","author":"Bhatt","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.cpcardiol.2024.102779_bib0046","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.jacc.2022.03.338","article-title":"Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized Trial","volume":"79","author":"Ghazi","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.cpcardiol.2024.102779_bib0047","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jacc.2023.02.005","article-title":"Cluster-Randomized Trial Comparing Ambulatory Decision Support Tools to Improve Heart Failure Care","volume":"81","author":"Mukhopadhyay","year":"2023","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624004134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280624004134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T05:25:41Z","timestamp":1726723541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280624004134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0146280624004134"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102779","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-hospital initiation of sodium-glucose cotransporter-2 inhibitors in patients with heart failure and reduced ejection fraction: 90-day prescription patterns and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102779"}}